Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SVF injection plus phototherapy for treatment-resistant vitiligo
IRCT20250630066310N2Phase 3Completed
- Sponsor
- Mashhad University of Medical Sciences
- Start
- Jun 2025
- Modality
- Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of autologous adipose stromal vascular fraction in Vitiligo, sponsored by Mashhad University of Medical Sciences. Primary endpoint: Repigmentation rate after SVF injection in white vitiligo lesions. Started Jun 2025; status: completed.
02
Drugs
autologous adipose stromal vascular fraction
03
Conditions
Vitiligo
Beyond the preview
Go deeper on IRCT20250630066310N2.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20250630066310N2.